Literature DB >> 18288991

Role of sulfonamide group in matrix metalloproteinase inhibitors.

Xian-Chao Cheng1, Qiang Wang, Hao Fang, Wen-Fang Xu.   

Abstract

Sulfonamide hydroxamates were designed and synthesized as efficient matrix metalloproteinase (MMP) inhibitors since the discovery of CGS 27023A in 1994. The sulfonamide group was incorporated in the inhibitor to improve the enzyme-inhibitor binding, not only by forming hydrogen bonds to the enzyme but also by properly directing the hydrophobic substituent to the S1' pocket and enabling it to plunge in deeply. Some researchers even presumed that the sulfonamide group, together with the zinc binding group (ZBG), coordinated the zinc ion within the MMP active site. This review will illustrate the role of the sulfonamide group in MMP inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288991     DOI: 10.2174/092986708783497300

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  9 in total

1.  In vitro comparison of new bisphosphonic acids and zoledronate effects on human gingival fibroblasts viability, inflammation and matrix turnover.

Authors:  Marianna De Colli; Paolo Tortorella; Guya Diletta Marconi; Mariangela Agamennone; Cristina Campestre; Marilena Tauro; Amelia Cataldi; Susi Zara
Journal:  Clin Oral Investig       Date:  2015-12-22       Impact factor: 3.573

2.  Preparation of Novel Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine Sulfonamides and Their Experimental and Computational Biological Studies.

Authors:  Mateusz Kciuk; Somdutt Mujwar; Anna Szymanowska; Beata Marciniak; Karol Bukowski; Mariusz Mojzych; Renata Kontek
Journal:  Int J Mol Sci       Date:  2022-05-24       Impact factor: 6.208

3.  Stable overexpression of DNA fragmentation factor in T-47D cells: sensitization of breast cancer cells to apoptosis in response to acetazolamide and sulfabenzamide.

Authors:  Fatemeh Bagheri; Shahrokh Safarian; Mohamadreza Baghaban Eslaminejad; Nader Sheibani
Journal:  Mol Biol Rep       Date:  2014-08-03       Impact factor: 2.316

4.  Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.

Authors:  Yonghao Jin; Mark D Roycik; Dale B Bosco; Qiang Cao; Manuel H Constantino; Martin A Schwartz; Qing-Xiang Amy Sang
Journal:  J Med Chem       Date:  2013-05-16       Impact factor: 7.446

5.  Potent and selective inhibitors for M32 metallocarboxypeptidases identified from high-throughput screening of anti-kinetoplastid chemical boxes.

Authors:  Emir Salas-Sarduy; Lionel Urán Landaburu; Adriana K Carmona; Juan José Cazzulo; Fernán Agüero; Vanina E Alvarez; Gabriela T Niemirowicz
Journal:  PLoS Negl Trop Dis       Date:  2019-07-22

Review 6.  Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review.

Authors:  Chuang Zhao; K P Rakesh; L Ravidar; Wan-Yin Fang; Hua-Li Qin
Journal:  Eur J Med Chem       Date:  2018-11-22       Impact factor: 6.514

7.  (2-Aminobenzothiazole)-Methyl-1,1-Bisphosphonic Acids: Targeting Matrix Metalloproteinase 13 Inhibition to the Bone.

Authors:  Antonio Laghezza; Luca Piemontese; Leonardo Brunetti; Alessia Caradonna; Mariangela Agamennone; Fulvio Loiodice; Paolo Tortorella
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-24

8.  Targeting matrix metallopeptidase 2 by hydroxyurea selectively kills acute myeloid mixed-lineage leukemia.

Authors:  Ruiheng Wang; Shufeng Xie; Shouhai Zhu; Yong Sun; Bowen Shi; Dan Li; Ting Kang; Yuanli Wang; Zhenshu Xu; Han Liu
Journal:  Cell Death Discov       Date:  2022-04-08

9.  Potential of Matrix Metalloproteinase Inhibitors for the Treatment of Local Tissue Damage Induced by a Type P-I Snake Venom Metalloproteinase.

Authors:  Lina María Preciado; Jaime Andrés Pereañez; Jeffrey Comer
Journal:  Toxins (Basel)       Date:  2019-12-20       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.